Figure 1:

Comprehensive molecular and cellular profiling of cervical cancer. (A) Study design. Created in BioRender. Sandoval, T. (2025) https://BioRender.com/esr0ns9 (B) Description of patients in Cohort 1, ancestry, HPV status, time points collected. (C-D) WES analysis of Cohort 1 pretreatment tumor biopsies: (C) Analysis of mutations of genes commonly altered in cervical cancer, number of samples with alterations (on top), mutation types and HPV status (D) Single-base substitution mutational signatures (SBS) associated with HPV-driven mutagenesis (E) Sample description in Cohort 2, case identification, HPV status, time points collected; singlets are samples with only one time of collection, triplets are samples collected at the three time points. (F) scRNA-seq dimensionality reduction UMAP for samples in Cohort 2 showing tumor, immune, and stroma clusters. (G) HPV Enrichment Mapping-based transcriptomic profiling, identifying HPV16, HPV18, and HPV45 expression. (H) Tumor cell sub-clustering colored by case identification (Left) and histology (Right) (I) Enrichment map network of pre-ranked GSEA pathways derived from tumor-cell DEGs. Tumor-cell DEGs were ranked by log₂ fold change and subjected to Gene Set Enrichment Analysis (GSEA), and significantly enriched pathways (FDR < 0.25) were visualized in Cytoscape using the EnrichmentMap plugin. In the network, each node represents a pathway (node size ∝ gene-set size; node color ∝ normalized enrichment score), and edges connect pathways sharing common genes, See Table S1. (J) CD274 (PD-L1) expression and percentage of CD274-expressing cells.